The Latest Breaking News from Boston Scientific

Settlement of two Australian class actions is largest in country’s history and subject to federal court approval

U.S. crude oil futures traded lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Over the past 3 months, 5 analysts have published their opinion on Boston Scientific (NYSE:BSX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Boston Scientific Corporation (NYSE:BSX) has agreed to purchase Synergy Innovation Co Ltd's majority stake (~64%) of M.I.Tech Co Ltd, a publicly-traded Korean manufacturer, and distributor of medical devices for endoscopic and urologic procedures.  The deal is valued at KRW 14,500 per share, representing KRW 291.2 billion or approximately $230 million. M.I.Tech offers HANAROSTENT technology, a…

Boston Scientific (NYSE:BSX) has outperformed the market over the past 10 years by 9.09% on an annualized basis producing an average annual return of 20.41%. Currently, Boston Scientific has a market capitalization of $53.12 billion.

Boston Scientific's (NYSE:BSX) short percent of float has risen 20.45% since its last report. The company recently reported that it has 15.00 million shares sold short, which is 1.06% of all regular shares that are available for trading.

Boston Scientific (NYSE:BSX) has observed the following analyst ratings within the last quarter:

Boston Scientific (NYSE:BSX) has outperformed the market over the past 10 years by 9.68% on an annualized basis producing an average annual return of 21.79%. Currently, Boston Scientific has a market capitalization of $58.91 billion.

Upgrades